Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma

International Journal of Hematology

Volumn 83, Issue 4, 2006, Pages 341-347

  Ohno, Toshihito ^a   Hiraga, Junji ^a   Ohashi, Haruhiko ^b   Sugisaki, Chiho ^a   Li, Eika ^a   Asano, Haruhiko ^a   Ito, Tastuya ^a   Nagai, Hirokazu ^b   Yamashita, Yoriko ^a   Mori, Naoyoshi ^a   Kinoshita, Tomohiro ^a   Naoe, Tomoki ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGOYA MEDICAL CENTER   (Japan)

Author keywords

Diffuse large B cell lymphoma; Expression; Hypermethylation; MGMT

Indexed keywords

CYCLOPHOSPHAMIDE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PIRARUBICIN; PREDNISONE; TUMOR MARKER; VINCRISTINE; ALKYLATING AGENT; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DIFFUSE LARGE B CELL LYMPHOMA; DISEASE FREE SURVIVAL; DNA METHYLATION; FEMALE; GENE; GENE LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MGMT GENE; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; TREATMENT RESPONSE; BIOSYNTHESIS; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; LARGE CELL LYMPHOMA; MIDDLE AGED; MORTALITY; PROTEIN SYNTHESIS; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DNA METHYLATION; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM PROTEINS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PROGNOSIS; PROMOTER REGIONS (GENETICS); PROTEIN BIOSYNTHESIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33744479180     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05182     Document Type: Article

References (41)

1. 6-alkylguanine-DNA alkyltransferase. Prog Nucleic Acid Res Mol Biol. 1995;51:167-223.
2. 6-methylguanine-DNA methyltransferase activity in brain tumors and adjacent normal brain. Cancer Res. 1993;53:3416-3420.
3. Belanich M, Pastor M, Randall T, et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res. 1996;56:783-788.
4. 6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998;77: 919-922.
5. 6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res. 1998;58: 1068-1073.
6. 6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol. 1998;16:3310-3315.
7. 6-methylguanine-DNA methyltransferase-deficient phenotype in human gliomas: frequency and time to tumor progression after alkylating agent-based chemotherapy. Clin Cancer Res. 1999;5: 807-814.
8. 6-alkylguanine. FASEB J. 1992;6:2302-2310.
9. 6-methylguanine DNA methyltransferase (MGMT) CpG island is associated with heterochromatinization of the MGMT transcription start site and silencing of the gene. Mol Cell Biol. 1997;17:5612-5619.
10. 6-methylguanine-DNA methyltransferase gene. Cancer Res. 1997;57:3672-3677.
11. 6-methylguanine-DNA methyltransferase promoter region as a marker of gene silencing. Mol Carcinog. 1999;24:85-89.
12. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res. 1999;59:793-797.
13. Herfarth KK, Brent TP, Danam RP, et al. A specific CpG methylation pattern of the MGMT promoter region associated with reduced MGMT expression in primary colorectal cancers. Mol Carcinog. 1999;24:90-98.
14. 6- methylguanine-DNA methyltransferase: promoter hypermethylation associated with decreased expression and G:C to A:T mutations of p53 in brain tumors. Mol Carcinog. 2003;36:23-31.
15. 6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res. 2000;60:2368-2371.
16. 6-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res. 2001;61:4689-4692.
17. 6- Methylguanine-DNA methyltransferase promoter hypermethylation shifts the p53 mutational spectrum in non-small cell lung cancer. Cancer Res. 2001; 61:8113-8117.
18. Nakamura M, Watanabe T, Yonekawa Y, Kleihues P, Ohgaki H. Promoter methylation of the DNA repair gene MGMT in astrocytomas is frequently associated with G:C → A:T mutations of the TP53 tumor suppressor gene. Carcinogenesis. 2001;22:1715-1719.
19. 6-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst. 2002;94:26-32.
20. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med. 2000;343:1350-1354.
21. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821-9826.
22. 6-alkylguanine-DNA alkyltransferase using newly developed monoclonal antibodies. Cancer Res. 1990; 50:58-61.
23. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
24. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31:1860-1861.
25. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7:1630-1636.
26. Mori M, Kitamura K, Masuda M, et al. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THP-COPE regimens in elderly patients with non-Hodgkin's lymphoma. Int J Hematol. 2005;81:246-254.
27. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981;29:577-580.
28. Hashimoto M, Yamashita Y, Mori N. Immunohistochemical detection of CD79a expression in precursor T cell lymphoblastic lymphoma/leukaemias. J Pathol. 2002;197:341-347.
29. Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood. 1997;89:272-280.
30. Kees UR, Burton PR, Lu C, Baker DL. Homozygous deletion of the p16/MTS1 gene in pediatric acute lymphoblastic leukemia is associated with unfavorable clinical outcome. Blood. 1997;89:4161-4166.
31. Wong IH, Ng MH, Huang DP, Lee JC. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood. 2000;95:1942-1949.
32. Sanchez-Beato M, Saez AI, Navas IC, et al. Overall survival in aggressive B-cell lymphomas is dependent on the accumulation of alterations in p53, p16, and p27. Am J Pathol. 2001;159:205-213.
33. INK4a gene deletions in pediatric acute lymphoblastic leukemia. Blood. 2001;97:4002-4004.
34. CIP1/WAF1/SD11 gene and confers pOor prognosis in acute lymphoblastic leukemia. Blood. 2002;99:2291-2296.
35. INK4B gene in myelodysplastic syndromes. Blood. 1997;90: 1403-1409.
36. Kawano S, Miller CW, Gombart AF, et al. Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood. 1999;94:1113-1120.
37. Katzenellenbogen RA, Baylin SB, Herman JG. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood. 1999;93:4347-4353.
38. Singal R, Ginder GD. DNA methylation. Blood. 1999;93:4059-4070.
39. Toyota M, Kopecky KJ, Toyota MO, Jair KW, Willman CL, Issa JP. Methylation profiling in acute myeloid leukemia. Blood. 2001;97: 2823-2829.
40. Roman J, Castillejo JA, Jimenez A, et al. Hypermethylation of the calcitonin gene in acute lymphoblastic leukaemia is associated with unfavourable clinical outcome. Br J Haematol. 2001;113:329-338.
41. Kinoshita T. Epigenetic inactivation of tumor suppressor genes in hematologic malignancies. Int J Hematol. 2004;80:108-119.